![]() ![]() We have seen an increasing number of customers specifically seeking truly rapid disintegration and superior palatability in order to differentiate their products in Japan’s competitive market. Hans-Joachim Rohe, President of Catalent Japan added, “We are very excited with the growing demand for Catalent’s Zydis® ODT in Japan, where many products could benefit from this type of ODT formulation. Abilify® OD is the 8th drug approved and launched in Japan, using Catalent’s Zydis® ODT.” As patient medication compliance is critical for those requiring antipsychotic therapies, Otsuka believes this new formulation will be of great assistance to patients in Japan. Catalent’s Zydis® fast dissolve technology has provided a tablet that is very palatable, and disintegrates within seconds in the mouth, making it very easy to take. ![]() Ian Muir, President of Catalent’s Modified Release Technology business stated, “We are delighted to partner with Otsuka on the launch of this important new formulation of Abilify® OD. Otsuka is one of the leading innovative pharmaceutical companies in Japan and has developed Abilify® OD for the treatment of schizophrenia and improvement of manic symptoms associated with bipolar disorder.Īdditionally, to support the increasing demand for Zydis® ODT formulations from the Japanese market, Catalent intends to make multi-million dollar investments to its Zydis® ODT operations in Swindon, UK.Ĭommenting on the new launch and investments, Dr. of Abilify® OD Tablets (orally disintegrating tablets (ODT)), which utilize Catalent’s Zydis® fast dissolve drug delivery technology. ![]() Somerset, NJ, JCatalent announced it has commenced supply to Otsuka Pharmaceutical Co., Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |